Hunter Perkins Capital Management LLC Raises Stock Position in Stryker Co. (NYSE:SYK)

Hunter Perkins Capital Management LLC boosted its position in shares of Stryker Co. (NYSE:SYK) by 17.7% in the first quarter, HoldingsChannel reports. The fund owned 15,495 shares of the medical technology company’s stock after purchasing an additional 2,325 shares during the quarter. Hunter Perkins Capital Management LLC’s holdings in Stryker were worth $3,774,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Liberty Capital Management Inc. lifted its holdings in shares of Stryker by 10.7% during the 1st quarter. Liberty Capital Management Inc. now owns 8,319 shares of the medical technology company’s stock valued at $2,026,000 after purchasing an additional 805 shares during the last quarter. Sawtooth Solutions LLC raised its stake in Stryker by 14.9% in the fourth quarter. Sawtooth Solutions LLC now owns 10,008 shares of the medical technology company’s stock valued at $2,452,000 after buying an additional 1,300 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its holdings in Stryker by 1.0% in the fourth quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,339,824 shares of the medical technology company’s stock worth $328,311,000 after acquiring an additional 13,604 shares in the last quarter. Dupont Capital Management Corp purchased a new stake in shares of Stryker during the fourth quarter worth about $4,885,000. Finally, Public Employees Retirement System of Ohio increased its holdings in shares of Stryker by 7.5% during the fourth quarter. Public Employees Retirement System of Ohio now owns 203,242 shares of the medical technology company’s stock valued at $49,802,000 after acquiring an additional 14,117 shares in the last quarter. Institutional investors own 71.46% of the company’s stock.

Shares of Stryker stock opened at $263.10 on Tuesday. The business’s fifty day simple moving average is $249.13 and its 200-day simple moving average is $238.13. The company has a quick ratio of 2.15, a current ratio of 2.89 and a debt-to-equity ratio of 0.92. The firm has a market cap of $99.12 billion, a PE ratio of 57.07, a price-to-earnings-growth ratio of 2.79 and a beta of 0.87. Stryker Co. has a 52 week low of $171.75 and a 52 week high of $268.04.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Monday, April 26th. The medical technology company reported $1.93 earnings per share for the quarter, missing analysts’ consensus estimates of $1.99 by ($0.06). Stryker had a net margin of 12.35% and a return on equity of 20.94%. The company had revenue of $3.95 billion for the quarter, compared to analyst estimates of $3.94 billion. During the same quarter in the prior year, the business earned $1.84 earnings per share. Stryker’s revenue was up 10.2% on a year-over-year basis. As a group, equities analysts expect that Stryker Co. will post 7.18 earnings per share for the current year.

In related news, VP M Kathryn Fink sold 4,000 shares of Stryker stock in a transaction on Thursday, April 8th. The stock was sold at an average price of $250.00, for a total value of $1,000,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Glenn S. Boehnlein sold 2,000 shares of the business’s stock in a transaction on Monday, March 1st. The stock was sold at an average price of $246.01, for a total value of $492,020.00. Following the transaction, the chief financial officer now directly owns 12,321 shares of the company’s stock, valued at $3,031,089.21. The disclosure for this sale can be found here. Insiders own 6.80% of the company’s stock.

Several analysts have weighed in on SYK shares. Citigroup boosted their target price on shares of Stryker from $264.00 to $303.00 in a research report on Wednesday, April 28th. Wells Fargo & Company upped their target price on Stryker from $265.00 to $300.00 and gave the company an “overweight” rating in a research report on Tuesday. Canaccord Genuity lifted their price target on Stryker from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Tuesday. Truist increased their price objective on Stryker from $245.00 to $255.00 in a report on Wednesday, April 28th. Finally, Robert W. Baird lifted their target price on Stryker from $265.00 to $292.00 and gave the stock an “outperform” rating in a report on Wednesday, April 28th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $261.59.

About Stryker

Stryker Corp. engages in the provision of medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems. The MedSurg segment deals with surgical equipment and navigation systems, endoscopy, patient handling and reprocessed medical devices.

Featured Story: Futures Contract

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.